Clinical trial
Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or…
NCT00095199 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00095199 |
|---|---|
| Title | Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer |
| Official title | Randomized Phase III Study of Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer After Platinum-Based Therapy |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Non Small Cell Lung Cancer |
| Intervention type | Biological, Drug |
| Interventions | Pemetrexed, Cetuximab, Docetaxel |
| Enrollment | 939 |
| Start date | Jan 1, 2005 |
| Primary completion | Jul 1, 2011 |
| Completion | Jul 1, 2011 |
| First posted | Nov 2, 2004 |
| Last update posted | Oct 15, 2012 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: